Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534042 | 0.94 | EPHX2 (0.44) | MAPTEPHX2L3MBTL1KDM4ETRPV1 | |
| SCHEMBL249662 | 0.81 | MAPT (0.45) | MAPTEPHX2L3MBTL1KDM4ETRPV1 | |
| SCHEMBL14477632 | 0.80 | MEN1 (0.33) | KMT2AMEN1 | |
| SCHEMBL254957 | 0.80 | MAPT (0.56) | MAPTEPHX2L3MBTL1KDM4ETRPV1 | |
| SCHEMBL14551858 | 0.79 | ALDH1A1 (0.41) | MAPTALDH1A1ALOX15TSHRGPR3 | |
| SCHEMBL820257 | 0.77 | KIF11 (0.44) | TRPV1MAOBAOC3ALDH1A1TSHR | |
| SCHEMBL12874081 | 0.77 | MAPT (0.47) | MAPTEPHX2L3MBTL1KDM4ETRPV1 | |
| SCHEMBL1393571 | 0.76 | EPHX2 (0.42) | MAPTEPHX2L3MBTL1KDM4ETRPV1 | |
| SCHEMBL26998948 | 0.75 | AURKA (0.37) | MAPTEPHX2GPR3AURKATPX2 | |
| SCHEMBL17407517 | 0.75 | EPHX2 (0.47) | MAPTEPHX2GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9403782-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| US-9206131-B2 | Compounds having antiparasitic or anti-infectious activity | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2015-12-08 | — | — | US | disclosed |
| US-9181484-B2 | Compound having 2-fluorophenyloxymethane structure | DIC CORPORATION (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9161924-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150087847-A1 | COMPOUND HAVING 2-FLUOROPHENYLOXYMETHANE STRUCTURE | DIC CORPORATION (JP) | 2015-03-26 | — | — | US | disclosed |
| US-8980916-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140322195-A1 | Factor IXA Inhibitors | MERCK SHARP & DOHME LLC | 2014-10-30 | — | — | US | disclosed |
| US-20140219989-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-07 | — | — | US | disclosed |
| US-20140045888-A1 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8361959-B2 | Spiro-imidazolone derivatives as glucagon receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120115904-A1 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY | 2012-05-10 | — | — | US | disclosed |
| US-20120010237-A1 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA DBA THE DEPARTMENT OF VETERANS AFFAIRS | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140219989-A1 | FACTOR IXA INHIBITORS | F9, F12, F11 | MAPT 3872/4885EPHX2 363/4885L3MBTL1 4779/4885 |
| US-20140322195-A1 | Factor IXA Inhibitors | F9, F12, F11 | MAPT 3872/4885EPHX2 363/4885L3MBTL1 4779/4885 |
| US-20120010237-A1 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY | MASTL, RPS10, CBR3 | MAPT 4854/4885EPHX2 754/4885L3MBTL1 1389/4885 |
| US-20140045888-A1 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY | H1-10, RAB10, HDAC10 | MAPT 4850/4885EPHX2 1576/4885L3MBTL1 1364/4885 |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | MAPT 4626/4885EPHX2 2160/4885L3MBTL1 3278/4885 |
| US-20120115904-A1 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY | H1-10, RAB10, HDAC10 | MAPT 4850/4885EPHX2 1595/4885L3MBTL1 1393/4885 |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | MAPT 4552/4885EPHX2 2039/4885L3MBTL1 4070/4885 |
| US-20160185774-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | MAPT 2660/4885EPHX2 4066/4885L3MBTL1 643/4885 |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | MAPT 3393/4885EPHX2 3556/4885L3MBTL1 2887/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | MAPT 4552/4885EPHX2 2039/4885L3MBTL1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.